Five things for pharma marketers to know: Thursday, August 17, 2017

Share this content:

1. Express Scripts will limit the number and strength of opioids it covers for first-time users. The program, which is part of an effort to curb abuse, has been criticized by physicians. (AP)

2. Novo Nordisk's experimental diabetes drug, semaglutide, met the main goal of a clinical trial aimed at reducing glucose levels. The drug compared favorably against Eli Lilly's dulaglutide in combination with metformin. (Reuters)

3. A startup called Aledade, founded by former national coordinator for health IT Dr. Farzad Mostashari, has raised about $75 million. It collects patient data in a manner that allows doctors to see how much their care costs the healthcare system. (NYT)

4. Many therapies granted accelerated approval by the FDA lack solid evidence that they are safe and effective, according to a new study in JAMA. The researchers looked at accelerated approvals of 22 drugs. (Reuters)

5. People who have taken DNA tests and learned they are at risk for certain diseases and conditions rarely change behaviors that might lessen that risk, such as improving their diets or getting more exercise. (AP)  

Share this content:
Scroll down to see the next article